# Evaluation Prospectively the Level of Reduction in Cognitive Functions of Cancer Patients Who Are on Active Oncology Treatments and Use Cannabis. The Second Goal is to Identify High-risk Groups for Cognitive Impairment Due to Cannabis Use.

> **NCT01983267** · NA · COMPLETED · sponsor: **Rambam Health Care Campus** · enrollment: 100 (actual)

## Conditions studied

- 1- Cancer Patients During Chemotherapy Treatment
- 2- Use of Cannabis Comparing to Control Without Cannabis Use

## Interventions

- **DRUG:** cannabis

## Key facts

- **NCT ID:** NCT01983267
- **Lead sponsor:** Rambam Health Care Campus
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-11
- **Primary completion:** 2017-04-26
- **Final completion:** 2017-04-26
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2017-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01983267

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01983267, "Evaluation Prospectively the Level of Reduction in Cognitive Functions of Cancer Patients Who Are on Active Oncology Treatments and Use Cannabis. The Second Goal is to Identify High-risk Groups for Cognitive Impairment Due to Cannabis Use.". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01983267. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*